In particular, LPS activates pathways that are directly involved in the progression of Crohn’s disease and ulcerative colitis, particularly the NF-κB pathway, which increases levels of IL-1, IL-6, and TNF-α, among others. Here, IL6 is linked to ulcerative colitis.